Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. [electronic resource]
Producer: 20170106Description: 1311-8 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Azacitidine -- administration & dosage
- Chromosome Aberrations
- Cytarabine -- administration & dosage
- Decitabine
- Disease Progression
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Epigenesis, Genetic -- drug effects
- Female
- Humans
- Idarubicin -- administration & dosage
- Leukemia, Myeloid, Acute -- diagnosis
- Male
- Middle Aged
- Mutation
- Myelodysplastic Syndromes -- diagnosis
- Recurrence
- Remission Induction
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.